On Friday, Intellia Therapeutics Inc (NASDAQ: NTLA) opened higher 11.00% from the last session, before settling in for the closing price of $9.64. Price fluctuations for NTLA have ranged from $8.96 to $34.87 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 4.71%. Company’s average yearly earnings per share was noted 1.99% at the time writing. With a float of $95.97 million, this company’s outstanding shares have now reached $101.80 million.
Let’s determine the extent of company efficiency that accounts for 526 employees. In terms of profitability, gross margin is 82.41%, operating margin of -1247.99%, and the pretax margin is -1212.19%.
Intellia Therapeutics Inc (NTLA) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Intellia Therapeutics Inc is 5.73%, while institutional ownership is 91.81%. The most recent insider transaction that took place on Jan 29 ’25, was worth 2,642. In this transaction Director of this company sold 265 shares at a rate of $9.97, taking the stock ownership to the 19,468 shares. Before that another transaction happened on Jan 03 ’25, when Company’s VP, Chief Accounting Officer sold 1,372 for $12.18, making the entire transaction worth $16,711. This insider now owns 45,640 shares in total.
Intellia Therapeutics Inc (NTLA) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.36 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 1.99% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 2.76% during the next five years compared to -22.30% drop over the previous five years of trading.
Intellia Therapeutics Inc (NASDAQ: NTLA) Trading Performance Indicators
Check out the current performance indicators for Intellia Therapeutics Inc (NTLA). In the past quarter, the stock posted a quick ratio of 6.73. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 25.29.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.45, a number that is poised to hit -1.33 in the next quarter and is forecasted to reach -5.13 in one year’s time.
Technical Analysis of Intellia Therapeutics Inc (NTLA)
Looking closely at Intellia Therapeutics Inc (NASDAQ: NTLA), its last 5-days average volume was 2.71 million, which is a drop from its year-to-date volume of 2.98 million. As of the previous 9 days, the stock’s Stochastic %D was 52.61%. Additionally, its Average True Range was 0.72.
During the past 100 days, Intellia Therapeutics Inc’s (NTLA) raw stochastic average was set at 13.41%, which indicates a significant decrease from 88.32% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 79.76% in the past 14 days, which was higher than the 77.00% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $11.49, while its 200-day Moving Average is $18.99. However, in the short run, Intellia Therapeutics Inc’s stock first resistance to watch stands at $11.15. Second resistance stands at $11.59. The third major resistance level sits at $12.26. If the price goes on to break the first support level at $10.04, it is likely to go to the next support level at $9.37. Now, if the price goes above the second support level, the third support stands at $8.92.
Intellia Therapeutics Inc (NASDAQ: NTLA) Key Stats
There are currently 101,849K shares outstanding in the company with a market cap of 1.09 billion. Presently, the company’s annual sales total 36,280 K according to its annual income of -481,190 K. Last quarter, the company’s sales amounted to 9,110 K and its income totaled -135,710 K.
